Therapeutic Advances in Gastroenterology · Sep 29, 2026

The potential benefit of sodium glucose cotransporter (SGLT)-2 inhibitors in liver cirrhosis: A mini review

By Spaan M, Meijnikman AS, van Raalte DH et al.

Liver cirrhosis represents a growing global health burden and prognosis is determined by the severity of portal hypertension and the development of complications. Among these, kidney dysfunction stands out as one of the strongest predictors of mortality. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated robust kidney and cardiovascular benefits across diverse populations, and early evidence suggests potential applicability in cirrhosis. This mini review synthesizes current knowledge on the natural history of kidney function decline in cirrhosis, modifiable risk factors, and the emerging rationale for SGLT2 inhibitor therapy in this high-risk population.

doi.org/10.1177/17562848261485144Open accessPubMed 43036466Interventions

AgingResearch.News